Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce the involvement of its entire team to support fight against Respiratory Syncytial Virus (RSV).
Even if RSV is a common respiratory virus that usually causes mild, cold-like symptoms, infants and older adults are more likely to develop severe RSV and need hospitalization. With the availability of new preventive therapies like a maternal vaccine (Abrysvo) and a mAb (Beyfortus), a reduction in medically attended lower respiratory tract infections in infants and children has been observed. It nevertheless required robust technologies to diagnose and precisely genotype infecting RSV viruses for optimal monitoring and epidemiological studies.
ABL Diagnostics, supports the fight against RSV infection through solutions combining PCR assay and a downstream analysis software intended to be used for an acute screening of RSV mutations. Its DeepChek Assay Whole Genome RSV Genotyping (https://www.abldiagnostics.com/products/deepchek-assay-rsv-genotyping/) is a Next Generation Sequencing Assay designed to target all relevant genes from the RSV virus and used to perform genotyping, polymorphisms characterization from upper respiratory specimens.
“The assay has been successfully used and validated by a reference laboratory (CHI Toulon, France) who multiplexed RSV samples with Influenza A/B samples, to detect the related mutations and construct phylogenetic trees. This work has been published at the European Meeting on HIV & Hepatitis 2024 in Barcelona (https://www.abldiagnostics.com/wp-content/uploads/2024/05/Poster-72_European-Meeting-on-HIV-Hepatitis-Barcelona-2024.pdf)” said Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics.
“We keep supporting all initiatives to optimize the management of RSV infection. For example, we have endorsed the International Workshop on Pediatric RSV Infection 2024, which will be held in Munich on July 20, 2024 (amededu.co/4byiujX)”, confirmed Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.